These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 15963677)

  • 1. Validation of immunoassays used to assess immunogenicity to therapeutic monoclonal antibodies.
    Geng D; Shankar G; Schantz A; Rajadhyaksha M; Davis H; Wagner C
    J Pharm Biomed Anal; 2005 Sep; 39(3-4):364-75. PubMed ID: 15963677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products.
    Shankar G; Devanarayan V; Amaravadi L; Barrett YC; Bowsher R; Finco-Kent D; Fiscella M; Gorovits B; Kirschner S; Moxness M; Parish T; Quarmby V; Smith H; Smith W; Zuckerman LA; Koren E
    J Pharm Biomed Anal; 2008 Dec; 48(5):1267-81. PubMed ID: 18993008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of an immunoassay for human-specific quantitation of therapeutic antibodies in serum samples from non-human primates.
    Stubenrauch K; Wessels U; Lenz H
    J Pharm Biomed Anal; 2009 May; 49(4):1003-8. PubMed ID: 19250787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Solution ELISA as a platform of choice for development of robust, drug tolerant immunogenicity assays in support of drug development.
    Mikulskis A; Yeung D; Subramanyam M; Amaravadi L
    J Immunol Methods; 2011 Feb; 365(1-2):38-49. PubMed ID: 21130095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of double antigen bridging immunoassay format on antigen coating concentration dependence and implications for designing immunogenicity assays for monoclonal antibodies.
    Bourdage JS; Lee TN; Taylor JM; Willey MB; Brandt JT; Konrad RJ
    J Pharm Biomed Anal; 2005 Sep; 39(3-4):685-90. PubMed ID: 15927431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vailidation of immunoassays for anti-drug antibodies.
    Van Cleave VH
    Dev Biol (Basel); 2003; 112():107-12. PubMed ID: 12762509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of immunoassay for protein biomarkers: bioanalytical study plan implementation to support pre-clinical and clinical studies.
    Valentin MA; Ma S; Zhao A; Legay F; Avrameas A
    J Pharm Biomed Anal; 2011 Jul; 55(5):869-77. PubMed ID: 21530130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of dried blood spots for the quantification of therapeutic monoclonal antibodies and detection of anti-drug antibodies.
    Kaendler K; Warren A; Lloyd P; Sims J; Sickert D
    Bioanalysis; 2013 Mar; 5(5):613-22. PubMed ID: 23425276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction of matrix interferences by the combination of chaotropic salt and DMSO in a broadly applicable target-based ELISA for pharmacokinetic studies of therapeutic monoclonal antibodies.
    Doucet J; Canadi J; Kalis C; Valentin MA; Marrony S; Deckert-Salva F; Legay F; Avrameas A
    J Pharm Biomed Anal; 2009 Dec; 50(5):924-31. PubMed ID: 19608373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation in pharmaceutical analysis. Part II: Central importance of precision to establish acceptance criteria and for verifying and improving the quality of analytical data.
    Ermer J; Ploss HJ
    J Pharm Biomed Anal; 2005 Apr; 37(5):859-70. PubMed ID: 15862659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products.
    Mire-Sluis AR; Barrett YC; Devanarayan V; Koren E; Liu H; Maia M; Parish T; Scott G; Shankar G; Shores E; Swanson SJ; Taniguchi G; Wierda D; Zuckerman LA
    J Immunol Methods; 2004 Jun; 289(1-2):1-16. PubMed ID: 15251407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and inhibition of drug target interference in immunogenicity assays.
    Zhong ZD; Dinnogen S; Hokom M; Ray C; Weinreich D; Swanson SJ; Chirmule N
    J Immunol Methods; 2010 Apr; 355(1-2):21-8. PubMed ID: 20188106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulatory considerations for development of bioanalytical assays for biotechnology products.
    Swann PG; Shapiro MA
    Bioanalysis; 2011 Mar; 3(6):597-603. PubMed ID: 21417729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing specificity for immunogenicity assays.
    Swanson SJ; Chirmule N
    Bioanalysis; 2009 Jun; 1(3):611-7. PubMed ID: 21083156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Confirming human antibody responses to a therapeutic monoclonal antibody using a statistical approach.
    Neyer L; Hiller J; Gish K; Keller S; Caras I
    J Immunol Methods; 2006 Aug; 315(1-2):80-7. PubMed ID: 16935294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a sensitive, rapid, biotin-streptavidin based chemiluminescent enzyme immunoassay for human thyroid stimulating hormone.
    Lin Z; Wang X; Li ZJ; Ren SQ; Chen GN; Ying XT; Lin JM
    Talanta; 2008 May; 75(4):965-72. PubMed ID: 18585170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of antibodies against therapeutic proteins in the presence of residual therapeutic protein using a solid-phase extraction with acid dissociation (SPEAD) sample treatment prior to ELISA.
    Smith HW; Butterfield A; Sun D
    Regul Toxicol Pharmacol; 2007 Dec; 49(3):230-7. PubMed ID: 17869396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation, calibration, and specificity of quantitative D-dimer assays.
    Dempfle CE
    Semin Vasc Med; 2005 Nov; 5(4):315-20. PubMed ID: 16302152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A formal comparison of different methods for establishing cut points to distinguish positive and negative samples in immunoassays.
    Jaki T; Lawo JP; Wolfsegger MJ; Singer J; Allacher P; Horling F
    J Pharm Biomed Anal; 2011 Jul; 55(5):1148-56. PubMed ID: 21561734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics.
    Gupta S; Indelicato SR; Jethwa V; Kawabata T; Kelley M; Mire-Sluis AR; Richards SM; Rup B; Shores E; Swanson SJ; Wakshull E
    J Immunol Methods; 2007 Apr; 321(1-2):1-18. PubMed ID: 17307199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.